Date: 2014-09-23
Type of information: IPO
Company: ProQR Therapeutics (The Netherlands)
Investors:
Amount: $102 million (€79.3 million)
Funding type: IPO
Planned used: ProQR Therapeutics is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on cystic fibrosis.
Others: * On September 23, 2014, ProQR Therapeutics announced the closing of its initial public offering of 8,625,000 ordinary shares at a public offering price of $13.00 per share, which includes the exercise in full by the underwriters of their option to purchase 1,125,000 additional ordinary shares. The aggregate net proceeds to the Company, after underwriting discounts and commissions and other estimated offering expenses, will be approximately $102 million. The company's ordinary shares were approved for listing on the NASDAQ Global Market and began trading under the symbol "PRQR" on September 18, 2014. * On September 18, 2014, ProQR Therapeutics announced the pricing of its initial public offering of 7,500,000 ordinary shares at an initial public offering price of $13.00 per ordinary share. In addition, ProQR has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 ordinary shares from ProQR at the public offering price, less underwriting discounts and commissions. After deducting the underwriting discounts and commissions and other estimated offering expenses payable by ProQR, the net proceeds of the initial public offering are expected to be approximately $88.4 million. The offering is expected to close on or about September 23, 2014, subject to customary closing conditions.ProQR\'s ordinary shares have been approved for listing on the NASDAQ Global Market and are expected to begin trading under the symbol \"PRQR\" on September 18, 2014. Leerink Partners and Deutsche Bank Securities are acting as joint book-running managers for the offering. JMP Securities is acting as lead manager, and H.C. Wainwright & Co., LLC is acting as co-manager for the offering.
Therapeutic area:
